Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 5/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30046612 | 1.00 | LCK (0.39) | LCKCYP17A1AAK1BRAFALDH1A1 | |
| SCHEMBL21773060 | 0.83 | KMT2A (0.33) | ALDH1A1ALOX15CA1CA2 | |
| SCHEMBL30045577 | 0.82 | BRAF (0.39) | CYP17A1AAK1BRAFCA1CA2 | |
| SCHEMBL21783559 | 0.82 | BRAF (0.39) | CYP17A1AAK1BRAFCA1CA2 | |
| SCHEMBL23148155 | 0.82 | CYP17A1 (0.41) | LCKCYP17A1AAK1BRAFALDH1A1 | |
| SCHEMBL30046033 | 0.79 | LCK (0.43) | LCKCYP17A1AAK1BRAFALDH1A1 | |
| SCHEMBL21783402 | 0.79 | LCK (0.43) | LCKCYP17A1AAK1BRAFALDH1A1 | |
| SCHEMBL21783542 | 0.79 | CYP17A1 (0.39) | LCKCYP17A1AAK1BRAFALDH1A1 | |
| SCHEMBL21783487 | 0.78 | SCN1A (0.55) | — | |
| SCHEMBL30046623 | 0.78 | SCN1A (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112638879-B | Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents | 泽农医药公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-112638898-B | Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors | 泽农医药公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-04-20 | — | — | US | disclosed |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2020-08-25 | — | — | US | disclosed |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-05-21 | — | — | US | disclosed |
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | US | disclosed |
| WO-2020047312-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047323-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | SCN1A, SCN2A, SCN2B | LCK 1502/4885CYP17A1 2480/4885AAK1 3420/4885 |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | SCN1A, SCN2A, SCN2B | LCK 1129/4885CYP17A1 2782/4885AAK1 3637/4885 |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | SCN1A, SCN2A, SCN2B | LCK 1502/4885CYP17A1 2480/4885AAK1 3420/4885 |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN2A, SCN2B | LCK 1129/4885CYP17A1 2782/4885AAK1 3637/4885 |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | SCN1A, SCN2A, SCN2B | LCK 1129/4885CYP17A1 2782/4885AAK1 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.